Progyny Stock - Truist lifts price target ahead of earnings calendar
Published on 06/22/2026 at 14:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Earnings & Calendar Desk. Verified prior to publication on 06/22/2026, 14:57 CET. Details in the imprint.
Progyny (US74340E1038) sits on investors' watchlists at the start of the week. Truist Securities has raised its price target on the fertility-benefits specialist to $33 from $30 while reiterating a Buy rating, according to a MarketScreener summary of the Truist note.
All news and data on Progyny stock
From current analyst views to official filings, this hub bundles background and price data on Progyny for investors following the fertility-benefits provider.
What Truist now expects
In its latest update, Truist lifted its 12-month price target on Progyny shares to $33, up from $30, and kept a Buy recommendation in place, according to the analyst-summary item dated 06/22/2026 on MarketScreener.
The move suggests Truist sees further upside from current trading levels, even after Progyny stock recovered part of its spring weakness. The broker generally cites robust demand for fertility benefits and growing adoption among large employers in earlier notes.
Weekly outlook and earnings calendar
This Monday, attention around Progyny centers on the upcoming quarterly earnings window for US health-benefits names. Markets expect the company to report its next set of numbers in early August, in line with its historical reporting pattern.
Consensus compiled by several financial-data providers currently points to continued double-digit revenue growth for 2026 as more employers add specialized fertility coverage. Against this backdrop, investors will look for updated client counts, utilization trends and margin signals when Progyny next reports.
How Progyny makes its money
Progyny's core business is a fertility-benefits platform sold to employers, combining managed benefits plans with access to a curated network of fertility clinics and pharmacy support. Revenue is generated primarily from benefit-plan administration fees and related services paid by corporate clients.
Where the stock trades today
Progyny shares (US74340E1038) trade on the Nasdaq at around $30.00 as of 06/22/2026, 14:57 CET, implying a mid-cap valuation in the US health-care services segment.
Key facts on Progyny stock
- Company: Progyny Inc.
- ISIN: US74340E1038
- WKN: A2N9LN
- Ticker: PGNY
- Venue: Nasdaq
- Price (as of 06/22/2026, 14:57 CET): 30.00 USD
- Market cap: 2,800,000,000 USD (as of 06/22/2026)
- Sector / Industry: Health Care - Managed Health Care / Benefits
- Index membership: not a member of the S&P 500 or Nasdaq-100
- Next earnings date: 08/06/2026 (company guidance and calendar indications)
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
